Physician profile
Nawazish Ali Khan
NPI 1477753903
$439,155.70
in general payments reported to CMS, 2019-2025
29 companies · $865 in 2025
The $865 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $2,864 · 2021: $167 · 2022: $294K · 2023: $141K · 2024: $144 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $141K · Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $140,625.00 |
| Food and Beverage | $1,258.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $249,775.38 | 2022-2025 | |
| Servier Bioinnovation | $184,245.00 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $2,918.97 | 2019-2025 | Imfinzi, Enhertu |
| Genzyme Corporation | $416.70 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $247.00 | 2022-2023 | Xpovio |
| Incyte Corporation | $231.05 | 2023-2025 | Monjuvi, Monjuvi, Jakafi |
| Abbvie INC. | $156.07 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $142.96 | 2022-2025 | Libtayo |
| Syndax Pharmaceuticals, INC. | $136.73 | 2025 | Revuforj |
| Emd Serono, INC. | $118.13 | 2022 | |
| Alexion Pharmaceuticals, INC. | $118.00 | 2019 | |
| Celgene Corporation | $89.31 | 2019-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $75.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $70.45 | 2020-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $65.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.14 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $45.39 | 2025 | |
| Amgen INC. | $42.49 | 2019 | |
| Pharmaessentia USA Corporation | $31.83 | 2025 | Besremi |
| Blueprint Medicines Corporation | $25.79 | 2025 | Ayvakit |
| Puma Biotechnology, INC. | $23.73 | 2025 | |
| Kite Pharma, INC. | $22.17 | 2025 | Yescarta |
| Sumitomo Pharma America, INC. | $20.39 | 2025 | Orgovyx |
| Array Biopharma INC | $18.85 | 2025 | Tukysa, Braftovi, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2019 | |
| Lilly USA, LLC | $15.74 | 2019 | |
| Seagen INC. | $14.90 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nawazish Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.